These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 18067883)

  • 61. Efficient internalization of MHC class II-invariant chain complexes is not sufficient for invariant chain proteolysis and class II antigen presentation.
    Swier K; Miller J
    J Immunol; 1995 Jul; 155(2):630-43. PubMed ID: 7608541
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Direct observation of ligand recognition by T cells.
    Irvine DJ; Purbhoo MA; Krogsgaard M; Davis MM
    Nature; 2002 Oct; 419(6909):845-9. PubMed ID: 12397360
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The function of invariant chain in class II-restricted antigen presentation.
    Ceman S; Sant AJ
    Semin Immunol; 1995 Dec; 7(6):373-87. PubMed ID: 8775463
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Comparative study of the role of professional versus semiprofessional or nonprofessional antigen presenting cells in the rejection of vascularized organ allografts.
    Sundstrom JB; Ansari AA
    Transpl Immunol; 1995 Dec; 3(4):273-89. PubMed ID: 8665146
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Cathepsin S regulates class II MHC processing in human CD4+ HLA-DR+ T cells.
    Costantino CM; Ploegh HL; Hafler DA
    J Immunol; 2009 Jul; 183(2):945-52. PubMed ID: 19553543
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The cell biology of antigen processing and presentation.
    Brodsky FM; Guagliardi LE
    Annu Rev Immunol; 1991; 9():707-44. PubMed ID: 1910692
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Stimulation of T cells by antigen-presenting cells is kinetically controlled by antigenic peptide binding to major histocompatibility complex class II molecules.
    McConnell HM; Wada HG; Arimilli S; Fok KS; Nag B
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2750-4. PubMed ID: 7708718
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Endosomal localization of MHC class II-invariant chain complexes.
    Miller J
    Immunol Res; 1994; 13(4):244-52. PubMed ID: 7616052
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discoordinate surface expression of IFN-gamma-induced HLA class II proteins in nonprofessional antigen-presenting cells with absence of DM and class II colocalization.
    Muczynski KA; Anderson SK; Pious D
    J Immunol; 1998 Apr; 160(7):3207-16. PubMed ID: 9531276
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Inefficient peptide binding by cell-surface class II MHC molecules.
    Sherman MA; Weber DA; Spotts EA; Moore JC; Jensen PE
    Cell Immunol; 1997 Nov; 182(1):1-11. PubMed ID: 9427804
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Invariant chain prevents the HLA-DR-restricted presentation of a cytosolic peptide.
    Long EO; LaVaute T; Pinet V; Jaraquemada D
    J Immunol; 1994 Aug; 153(4):1487-94. PubMed ID: 8046228
    [TBL] [Abstract][Full Text] [Related]  

  • 72. DM and DO shape the repertoire of peptide-MHC-class-II complexes.
    Karlsson L
    Curr Opin Immunol; 2005 Feb; 17(1):65-70. PubMed ID: 15653313
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells.
    Morton PA; Zacheis ML; Giacoletto KS; Manning JA; Schwartz BD
    J Immunol; 1995 Jan; 154(1):137-50. PubMed ID: 7995933
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
    Vigna JL; Smith KD; Lutz CT
    J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Trafficking of MHC class II molecules in the late secretory pathway.
    Hiltbold EM; Roche PA
    Curr Opin Immunol; 2002 Feb; 14(1):30-5. PubMed ID: 11790530
    [TBL] [Abstract][Full Text] [Related]  

  • 76. MHC II and the endocytic pathway: regulation by invariant chain.
    Landsverk OJ; Bakke O; Gregers TF
    Scand J Immunol; 2009 Sep; 70(3):184-93. PubMed ID: 19703008
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The pathway for MHCII-mediated presentation of endogenous proteins involves peptide transport to the endo-lysosomal compartment.
    Dani A; Chaudhry A; Mukherjee P; Rajagopal D; Bhatia S; George A; Bal V; Rath S; Mayor S
    J Cell Sci; 2004 Aug; 117(Pt 18):4219-30. PubMed ID: 15316082
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A novel antigen-processing-defective phenotype in major histocompatibility complex class II-positive CIITA transfectants is corrected by interferon-gamma.
    Siegrist CA; Martinez-Soria E; Kern I; Mach B
    J Exp Med; 1995 Dec; 182(6):1793-9. PubMed ID: 7500024
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Invariant chain and DM edit self-peptide presentation by major histocompatibility complex (MHC) class II molecules.
    Katz JF; Stebbins C; Appella E; Sant AJ
    J Exp Med; 1996 Nov; 184(5):1747-53. PubMed ID: 8920863
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A mutant human histocompatibility leukocyte antigen DR molecule associated with invariant chain peptides.
    Mellins E; Cameron P; Amaya M; Goodman S; Pious D; Smith L; Arp B
    J Exp Med; 1994 Feb; 179(2):541-9. PubMed ID: 8294865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.